Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2017 1 321 572 M
EBIT 2017 275 000 M
Net income 2017 204 061 M
Finance 2017 465 287 M
Yield 2017 2,29%
Sales 2018 1 375 774 M
EBIT 2018 292 000 M
Net income 2018 208 943 M
Finance 2018 576 981 M
Yield 2018 2,44%
P/E ratio 2017 15,37
P/E ratio 2018 14,94
EV / Sales2017 2,10x
EV / Sales2018 1,94x
Capitalization 3 241 504 M
More Financials
Company
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products.Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic... 
More about the company
Surperformance© ratings of Astellas Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC
03/29 ASTELLAS PHARMA : Transfer of 16 Long-Listed Products in Japan
03/29 ASTELLAS PHARMA INC : ex-dividend day for final dividend
03/23 NEW CHROMATOGRAPHY STUDY FINDINGS HA : A Pitfall Associated...
03/23 ASTELLAS PHARMA : Findings from Astellas Pharma Provide New Insights into Urothe..
03/23 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
03/23 CYTOKINETICS : Announces Preclinical Data for CK-2127107 Presented at MDA Scient..
03/23 ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 189KB)
03/22 ASTELLAS PHARMA : Launch of LINZESS® Tablets 0.25mg in Japan
03/16 ASTELLAS PHARMA : Researchers from Astellas Pharma Discuss Findings in Liver Can..
03/13 ASTELLAS PHARMA : Work begins on new pneumococcus vaccine
More news
Sector news : Pharmaceuticals - NEC
11:07aDJOXFORD BIOMEDICA : Hails U.S. Regulatory Boost for Leukemia Treatment
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
More sector news : Pharmaceuticals - NEC
Latest Tweets
03/22Astellas Pharma : Launch of LINZESS® Tablets 0.25mg in Japan  
03/21Astellas pens pact to discover drugs in X-Chem’s library  
03/21Astellas pens pact to discover drugs in X-Chem’s library:
1
03/20X-Chem Announces Strategic Collaboration With Astellas Across Multiple Therap.. 
02/28Astellas, Affinivax team up to target Pfizer’s Prevnar  
More tweets
Qtime:19
News from SeekingAlpha
03/29 Cytokinetics advances mid-stage study of SMA candidate CK-2127107
02/10 More Lost Than Gained In Shifting R&D Forecasts
02/10 ASTELLAS PHARMA : A Contrarian Investment
02/03 Pfizer May Be Another IBM
02/02 Astellas Pharma Recommended By Charles De Vaulx Of IVA Funds
Advertisement
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 1 809  JPY
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Yasumasa Masuda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-7.44%29 144
JOHNSON & JOHNSON9.07%338 645
ROCHE HOLDING LTD.8.81%221 440
PFIZER INC.5.70%204 439
NOVARTIS AG-0.47%197 239
MERCK & CO., INC.8.10%174 728
More Results